InvestorsHub Logo

H2R

Followers 41
Posts 2214
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: None

Friday, 04/28/2017 11:28:43 AM

Friday, April 28, 2017 11:28:43 AM

Post# of 1570
VITALITY-ALS patients continue on Open Label Extension

Moreover, nearly all patients completing VITALITY-ALS are choosing to continue into the open label extension trial. We also advanced our innovative collaboration with Origent Data Sciences and we look forward to contributing data from VITALITY-ALS to Origent’s machine learning model that may ultimately help accelerate future clinical trials in ALS by providing predictive algorithms and potential efficiencies of the conduct of the trials. Andy will have more to say about that.



https://seekingalpha.com/article/4066517-cytokinetics-cytk-ceo-robert-blum-q1-2017-results-earnings-call-transcript?part=single
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTK News